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evidence that the patient had an acute
infection. However, observations that
the patient had no manifestation of
encephalitis during a previous episode
of neutropenia and that she had an
acute febrile illness associated with
neurologic signs of encephalitis point
to an acute infection. The figure, in
which WNV copy numbers are corre-
lated with leukocyte count, is not
intended to pinpoint the time of infec-
tion. However, as stated in the paper,
this figure did show that the virus was
rapidly cleared after resolution of
neutropenia.
A report by Camenga et al. (5)
demonstrated that mice, infected with
WNV develop only an inapparent
infection. These mice will invariably
die of fulminant encephalitis if only a
single dose of cyclophosphamide is
given. However, mice treated with
one dose of cyclophosphamide
demonstrate inflammatory changes in
the brain. If a second dose of the drug
is administered 5 days after infection,
inflammation is completely sup-
pressed in mice. Although mice are
immunologically different from
humans, this work, done almost 30
years ago, supports the argument for
an acute infection in the current case
report. If the patient in our study was
a chronic carrier, she should have had
manifestations of acute West Nile
encephalitis immediately following
the first course of combination
chemotherapy, which was much more
immunosuppressive than cyclophos-
phamide alone. This fact reempha-
sizes our major point in the article that
patients who are immunocompro-
mized and undergoing chemotherapy,
which may cause neutropenia, should
take extra precautions against being
exposed to WNV. 
Alexander Hindenburg* 
and Cinnia Huang†
*Winthrop University Hospital, Mineola,
New York, USA; †New York State
Department of Health, Albany, New York,
USA
References
1. Shieh WJ, Guarmer J, Layton M, Fine A,
Miller J, Nash D, et al. The role of patholo-
gy in an investigation of an outbreak of
West Nile encephalitis in New York, 1999.
Emerg Infect Dis 2000;6:370–2.
2. Sampson BA, Armbrustmacher V. West
Nile encephalitis. The neuropathology of
four fatalities. Ann NY Acad Sci
2001;951:172–8.
3. Southam CM, Moore AE. Induced virus
infections in man by the Egypt isolates of
West Nile virus. Am J Trop Med Hyg
1954;3:19–50.
4. Hindiyeh M, Shulman LM, Mendelson E,
Weiss L, Grossman Z, Bin H. Isolation and
characterization of West Nile virus from the
blood of viremic patients during the 2000
outbreak in Israel. Emerg Infect Dis
2001;7:748–50.
5. Camenga DL, Nathanson N, Cole GA.
Cyclophosphamide-potentiated West Nile
viral encephalitis: relative influence of cel-
lular and humoral factors. J Infect Dis
1974;130:634–41.
Address for correspondence: Alexander
Hindenburg, 200 Old Country Road, Mineola,
NY 11501, USA; fax: 516-663-4613; email:
ahindenb@winthrop.org
Emerging Infectious Diseases • Vol. 9, No. 5, May 2003 609
LETTERS
Correction Vol. 9, No. 4
In the article, “Antimicrobial Drug Prescriptions in Ambulatory Care Settings,
United States, 1992–2000” by Linda F. McCaig et al. errors occurred on pages
432, 434, and 446. On page 432, the correct affiliations are as follows: Linda F.
McCaig, National Center for Health Statistics, Centers for Disease Control and
Prevention (CDC), Hyattsville, Maryland, USA; Richard E. Besser and James M.
Hughes, National Center for Infectious Diseases, CDC, Atlanta, Georgia, USA.
In the abstract, the change in antimicrobial prescribing rate for amoxicillin/clavu-
lanate is +69%. On page 434, second paragraph, Results section, the correct first
sentence appears below:
During the study period, the antimicrobial prescribing rate at all ambulatory
care visits declined for amoxicillin and ampicillin (–43%; p<0.001),
cephalosporins (–28%; p<0.001), and erythromycin (–76%; p<0.001) (Figure 5);
the prescribing rate rose for azithromycin and clarithromycin (+388%; p<0.001),
quinolones among persons >15 years (+78%; p<0.001), and amoxicillin/clavu-
lanate  (+69%; p=0.004) (Figure 6). 
On page 436, the correct caption to Figure 6 appears below:
Trends in increasing annual antimicrobial prescribing rates by drug class—
United States, 1992–2000. Note: trend for amoxicillin/clavulanate p<0.001; for
quinolones among persons >15 years, p<0.001; for azithromycin and clar-
ithromycin among all ages, p<0.001.
The corrected article appears online at http://www.cdc.gov/ncidod/EID/
vol9no4/02-0268.htm. 
We regret any confusion these errors may have caused.
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